Citigroup
NMTR

Citigroup’s 9 Meters Biopharma NMTR Stock Holding History

Citigroup’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,487
Closed -$18K – 6526
2022
Q2 		$18K Buy
3,487
+2,585
+287% +$24.4K ﹤0.01% 5082
2022
Q1 		$11K Sell
902
-2,058
-70% -$28.1K ﹤0.01% 5498
2021
Q4 		$58K Buy
2,960
+1,586
+115% +$35.5K ﹤0.01% 4992
2021
Q3 		$36K Buy
1,374
+604
+78% +$14.2K ﹤0.01% 4931
2021
Q2 		$17K Sell
770
-39,230
-98% -$963K ﹤0.01% 5406
2021
Q1 		$936K Buy
+40,000
New +$1.23M ﹤0.01% 3038
2020
Q1 		– Sell
-116
Closed -$1K – 7831
2019
Q4 		$1K Hold
116
– – ﹤0.01% 7631
2019
Q3 		$2K Sell
116
-39
-25% -$788 ﹤0.01% 7566
2019
Q2 		$4K Sell
155
-124
-44% -$3.72K ﹤0.01% 7546
2019
Q1 		$10K Buy
279
+8
+3% +$346 ﹤0.01% 7262
2018
Q4 		$12K Buy
271
+17
+7% +$1.26K ﹤0.01% 7100
2018
Q3 		$35K Buy
254
+122
+92% +$21K ﹤0.01% 6803
2018
Q2 		$62K Buy
+132
New +$48.6K ﹤0.01% 6121

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Citigroup's NMTR Position: Q3 2022 in Review

Citigroup sold out of 9 Meters Biopharma (NMTR) in Q3 2022, closing a stake of 3,487 shares — an estimated $18K sold.

Citigroup first reported a position in NMTR in Q2 2018 and held it in 13 quarters. The position peaked at $936K in Q1 2021. 74 funds tracked by Wall St. Rank hold NMTR as of Q3 2022.

  • Citigroup reported no remaining 9 Meters Biopharma position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 3,487 9 Meters Biopharma shares in Q3 2022, an estimated $18K.
  • Citigroup first reported a position in 9 Meters Biopharma in Q2 2018 and held it in 13 quarters.
  • Citigroup's 9 Meters Biopharma position peaked at $936K in Q1 2021.
  • 74 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.